172 related articles for article (PubMed ID: 36361596)
1. MGL S3 Chimeric Enzyme Drives Apoptotic Death of EGFR-Dependent Cancer Cells through ERK Downregulation.
Bondarev N; Ivanenko K; Khabusheva E; Lebedev T; Manukhov I; Prassolov V
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361596
[TBL] [Abstract][Full Text] [Related]
2. Methionine gamma lyase fused with S3 domain VGF forms octamers and adheres to tumor cells via binding to EGFR.
Bondarev NA; Bagaeva DF; Bazhenov SV; Buben MM; Bulushova NV; Ryzhykau YL; Okhrimenko IS; Zagryadskaya YA; Maslov IV; Anisimova NY; Sokolova DV; Kuklin AI; Pokrovsky VS; Manukhov IV
Biochem Biophys Res Commun; 2024 Jan; 691():149319. PubMed ID: 38042033
[TBL] [Abstract][Full Text] [Related]
3. Gene cloning, characterization, and cytotoxic activity of methionine γ-lyase from Clostridium novyi.
Kulikova VV; Morozova EA; Revtovich SV; Kotlov MI; Anufrieva NV; Bazhulina NP; Raboni S; Faggiano S; Gabellieri E; Cioni P; Belyi YF; Mozzarelli A; Demidkina TV
IUBMB Life; 2017 Sep; 69(9):668-676. PubMed ID: 28681503
[TBL] [Abstract][Full Text] [Related]
4. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
6. Conjugates of methionine γ-lyase with polysialic acid: Two approaches to antitumor therapy.
Morozova E; Anufrieva N; Koval V; Lesnova E; Kushch A; Timofeeva V; Solovieva A; Kulikova V; Revtovich S; Demidkina T
Int J Biol Macromol; 2021 Jul; 182():394-401. PubMed ID: 33839182
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
8. Plasma methionine depletion and pharmacokinetic properties in mice of methionine γ-lyase from Citrobacter freundii, Clostridium tetani and Clostridium sporogenes.
Morozova EA; Anufrieva NV; Davydov DZ; Komarova MV; Dyakov IN; Rodionov AN; Demidkina TV; Pokrovsky VS
Biomed Pharmacother; 2017 Apr; 88():978-984. PubMed ID: 28178629
[TBL] [Abstract][Full Text] [Related]
9. De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy.
Stone E; Paley O; Hu J; Ekerdt B; Cheung NK; Georgiou G
ACS Chem Biol; 2012 Nov; 7(11):1822-9. PubMed ID: 22963240
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
11. Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6.
Gay F; Aguera K; Sénéchal K; Tainturier A; Berlier W; Maucort-Boulch D; Honnorat J; Horand F; Godfrin Y; Bourgeaux V
Cancer Med; 2017 Jun; 6(6):1437-1452. PubMed ID: 28544589
[TBL] [Abstract][Full Text] [Related]
12. Engineering methionine γ-lyase from Citrobacter freundii for anticancer activity.
Raboni S; Revtovich S; Demitri N; Giabbai B; Storici P; Cocconcelli C; Faggiano S; Rosini E; Pollegioni L; Galati S; Buschini A; Morozova E; Kulikova V; Nikulin A; Gabellieri E; Cioni P; Demidkina T; Mozzarelli A
Biochim Biophys Acta Proteins Proteom; 2018 Dec; 1866(12):1260-1270. PubMed ID: 30268810
[TBL] [Abstract][Full Text] [Related]
13. High Expression of the Lysosomal Protease Cathepsin D Confers Better Prognosis in Neuroblastoma Patients by Contrasting EGF-Induced Neuroblastoma Cell Growth.
Secomandi E; Salwa A; Vidoni C; Ferraresi A; Follo C; Isidoro C
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563171
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
[TBL] [Abstract][Full Text] [Related]
15. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
16. Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts.
Pokrovsky VS; Yu Anisimova N; Zh Davydov D; Bazhenov SV; Bulushova NV; Zavilgelsky GB; Kotova VY; Manukhov IV
Invest New Drugs; 2019 Apr; 37(2):201-209. PubMed ID: 29948359
[TBL] [Abstract][Full Text] [Related]
17. Effects in Cancer Cells of the Recombinant l-Methionine Gamma-Lyase from
Machover D; Rossi L; Hamelin J; Desterke C; Goldschmidt E; Chadefaux-Vekemans B; Bonnarme P; Briozzo P; Kopečný D; Pierigè F; Magnani M; Mollicone R; Haghighi-Rad F; Gaston-Mathé Y; Dairou J; Boucheix C; Saffroy R
J Pharmacol Exp Ther; 2019 Jun; 369(3):489-502. PubMed ID: 30940696
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
[TBL] [Abstract][Full Text] [Related]
19. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
[TBL] [Abstract][Full Text] [Related]
20. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Lu Y; Liang K; Li X; Fan Z
Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
